These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2245907)

  • 1. [Heparin: its mechanism of action and use in cardiology].
    Serneri GG; Rostagno C
    G Ital Cardiol; 1990 Jul; 20(7):670-4. PubMed ID: 2245907
    [No Abstract]   [Full Text] [Related]  

  • 2. [Regulatory role of heparin compounds with low molecular blood ligands in plasma and thrombocyte hemostasis].
    Liapina LA; Obergan TIu; Pastorova VE
    Izv Akad Nauk Ser Biol; 2011; (2):208-19. PubMed ID: 21506395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interaction of heparin and thrombocytes (a review of the Soviet and foreign literature)].
    Traskunova NV; Rokhmistrova VD
    Vestn Khir Im I I Grek; 1980 Apr; 124(4):142-6. PubMed ID: 6992400
    [No Abstract]   [Full Text] [Related]  

  • 4. [Does heparin exert any influence on the secretion of tissue blood coagulating factors from vascular walls?].
    Mishchenko VP
    Patol Fiziol Eksp Ter; 1970; 14(1):45-9. PubMed ID: 5453784
    [No Abstract]   [Full Text] [Related]  

  • 5. [From heparin to heparins: toward new therapeutic perspectives?].
    Molho P; Tobelem G
    Biomed Pharmacother; 1987; 41(4):171-5. PubMed ID: 3620582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of action of heparin].
    Collen D; Hoylaerts M; Lijnen HR
    Verh K Acad Geneeskd Belg; 1986; 48(1):33-49. PubMed ID: 3739420
    [No Abstract]   [Full Text] [Related]  

  • 7. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors.
    Kirchhofer D; Tschopp TB; Hadváry P; Baumgartner HR
    J Clin Invest; 1994 May; 93(5):2073-83. PubMed ID: 8182139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of thrombin and heparin activities by fibrin.
    Hogg PJ; Bock PE
    Thromb Haemost; 1997 Mar; 77(3):424-33. PubMed ID: 9065987
    [No Abstract]   [Full Text] [Related]  

  • 9. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits.
    Warn-Cramer BJ; Maki SL; Rapaport SI
    Thromb Haemost; 1993 Mar; 69(3):221-6. PubMed ID: 8470044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Heparin--its physiological action and use in the treatment of certain diseases].
    Burbanov G
    Vutr Boles; 1974; 13(1):1-13. PubMed ID: 4611028
    [No Abstract]   [Full Text] [Related]  

  • 11. [Activated coagulation time in the evaluation of anticoagulation with heparin in peripheral vascular surgery].
    Brandi LS; Nannoni L; Carmellini M; Ferrari M; Grana M; D'Elia F; Parra PF; Mosca F
    Minerva Cardioangiol; 1986 Apr; 34(4):273-7. PubMed ID: 3725034
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of epsilon-aminocaproic acid derivatives on the anticoagulant activity of heparin.
    Midura-Nowaczek K; Bruzgo I; Worowski K; Roszkowska-Jakimiec W
    Rocz Akad Med Bialymst; 1998; 43():228-31. PubMed ID: 9972059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of temperature, velocity gradient and I.V. heparin on in vitro blood coagulation and platelet aggregation.
    Dintenfass L; Rozenberg MC
    Thromb Diath Haemorrh; 1967 Feb; 17(1-2):112-9. PubMed ID: 5584945
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined dihydroergotamine and heparin prophylaxis of postoperative deep vein thrombosis: proposed mechanism of action.
    Comerota AJ; Stewart GJ; White JV
    Am J Surg; 1985 Oct; 150(4A):39-44. PubMed ID: 3901791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Importance of heparin in infants with consumption coagulation disease caused by septicemia].
    de Aquino-Jaso ME; Olvera-Hidalgo C; Ramírez JI
    Bol Med Hosp Infant Mex; 1974; 31(1):73-84. PubMed ID: 4433389
    [No Abstract]   [Full Text] [Related]  

  • 16. [Mechanism of the action of heparin on thrombocytes].
    Gromnatskiĭ NI
    Vrach Delo; 1969 Mar; 3():90-2. PubMed ID: 5369667
    [No Abstract]   [Full Text] [Related]  

  • 17. [Endothelial dysfunction and metabolic effects of nitric oxide in human].
    Kolesnichenko OIu; Filatova LM; Krivitsina ZA; Voronkov IuI
    Fiziol Cheloveka; 2003; 29(5):74-81. PubMed ID: 14611088
    [No Abstract]   [Full Text] [Related]  

  • 18. [Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer].
    Li J; Cong YL; Tu GH; Yang L; Zhu BB; Jin L
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1269-71. PubMed ID: 17686264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The non-anticoagulant action of heparins: prospects].
    Tobelem G
    Rev Prat; 1988 May; 38(15):957-60. PubMed ID: 2455930
    [No Abstract]   [Full Text] [Related]  

  • 20. [Blood coagulation studies during streptokinase, heparin and plasmin therapy].
    Perlick E; Conrad E; Zimmermann S; Müldner J; Bach H
    Z Gesamte Inn Med; 1968 Mar; 23(5):Suppl:80 c. PubMed ID: 4234981
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.